Aayush Agrawal, a promoter of Ajanta Pharma Limited, has announced the creation of a pledge on 11,25,000 equity shares and the release of a pledge on 10,25,000 equity shares. The creation of the pledge was for a new loan and top-up call, while the release was due to loan closure. This disclosure is made in compliance with SEBI (SAST) Regulations, 2011.
Ajanta Pharma Promoter Disclosure on Share Pledges
Aayush Agrawal, identified as a promoter of Ajanta Pharma Limited, has formally disclosed significant activities related to the encumbrance of the company’s shares. The disclosure, made under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, details both the creation and release of pledged equity shares. Specifically, a pledge has been created on a total of 11,25,000 equity shares, while simultaneously, a pledge on 10,25,000 equity shares has been released.
Reasons for Share Encumbrance
The rationale provided for the creation of the pledge is associated with securing a New Loan & Top up call. Conversely, the release of the previously pledged shares is attributed to Loan Closure. These actions reflect the promoter’s financial management strategies concerning their stake in Ajanta Pharma Limited. The company’s scrip codes are BSE – AJANTPHARM 532331 and NSE – AJANTPHARM EQ.
Details of Pledge Transactions
The detailed breakdown of these transactions, as reported, includes multiple instances of pledge creation and release. For instance, on November 2, 2026, a pledge was created on 1,21,32,386 equity shares (9.71% of total capital) with CTL Trusteeship Ltd as the beneficiary, citing a ‘Top up Call’ as the reason. Subsequently, on November 3, 2026, 1,22,32,386 equity shares (9.79% of total capital) were released due to a ‘Loan closed’ scenario, with Jio Credit Ltd being the entity favouring the earlier pledge. Further releases occurred on November 3 and 4, 2026, for loans closed with Jio Credit Ltd and Bajaj Finance Ltd respectively. New loan encumbrances were also noted on November 5 and 6, 2026, with Tata Capital Ltd as the beneficiary, involving amounts of ₹5,90,000, ₹3,85,000 and ₹50,000, representing 0.47%, 0.31%, and 0.04% of total share capital respectively.
Regulatory Compliance
This disclosure adheres to the requirements of Regulation 31(1) & 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, ensuring transparency in the promoter’s shareholding and pledge activities. The document was submitted to both the BSE Limited and the National Stock Exchange of India, with a copy also provided to the Company Secretary of Ajanta Pharma Limited.
Source: BSE
